503A
Undisclosed 503A partner
Ivim does not name its compounding pharmacy on the public site. The February 2026 FDA warning letter clarified that Ivim is not the compounder despite 'Ivim'-labeled product imagery on the site.
Columbus-based virtual GLP-1 program with membership model and large clinician team.
Pricing note: Membership $74.99/mo required. Compounded semaglutide medication starts ~$75/mo (total ~$150 with membership); compounded tirzepatide starts ~$133/mo (total ~$208). Brand path: Wegovy pill from $149/mo + $74.99 membership = ~$224/mo all-in per the published Wegovy pill page. Multi-month prepay reduces medication cost.
State availability: Mississippi excluded due to state telehealth laws regarding medical weight reduction (confirmed in published peer-reviewed study). Other states unrestricted.
Ivím Health is a national telehealth platform headquartered in Columbus, Ohio, offering personalized GLP-1 weight management and women's hormone replacement therapy. Founded in 2021 by Dr. Taylor Kantor (Co-Founder), Anthony S. Kantor (CEO/Co-Founder), and Kelly Kantor (CMO), the company operates through affiliated entities Ivim Services LLC, Ivim Health LLC, and Ivim Professional Corporation. The platform combines a recurring membership fee with separately priced compounded or branded GLP-1 medications, including semaglutide, tirzepatide, liraglutide, and brand-name options like Ozempic, Wegovy, Mounjaro, and Zepbound. Ivim publishes peer-reviewed clinical outcome studies in Obesity Pillars and reports a clinician network of nearly 100 licensed providers, including board-certified obesity medicine physicians and nurse practitioners. The model emphasizes app-based engagement, functional health coaching, and individualized dose titration (the 'GLP-1 ID' protocol). Ivim received an FDA warning letter on February 20, 2026 for misbranding compounded GLP-1 product labeling.
Specific compounding pharmacy partners not disclosed on ivimhealth.com. FDA warning letter (Feb 20, 2026) cited misleading 'Ivim'-labeled compounded product photos as misbranding under FDCA §502(a)/(bb).
Ivim does not name its compounding pharmacy on the public site. The February 2026 FDA warning letter clarified that Ivim is not the compounder despite 'Ivim'-labeled product imagery on the site.
We don’t republish individual user quotes — too easy to misattribute, too easy to lose context. Below are the aggregate ratings from public review platforms with links to read actual reviews at the source. Counts are rounded down to a confident floor (e.g. 12,788 → 12,000+).
Click any source above to read the actual reviews. Ratings reflect the platform’s own reported aggregate at last verification (May 6, 2026).
Per Subscription Agreement: month-to-month plans cancellable via website My Account, support email (support@ivimhealth.com), or text with at least 48 hours notice before renewal. Multi-month programs (2/4/6/12-month) are NOT cancellable mid-term — patient is contractually obligated to pay full duration; cancellation only available after final payment is made. Restocking fees of $50–$100 per undeveloped portion may apply per Returns Policy. Early cancellation requires extenuating circumstances reviewed by Patient Experience team.
Read official policy ↗Per Refund and Returns Policy: all prescribed medications are non-refundable and cannot be returned. Damaged/lost/stolen shipments must be reported within 48 hours. Supplements returnable within 30 days if unopened. Subscription fees are non-refundable once payment terms accepted; refunds for unshipped portions of multi-month plans subject to $50–$100 restocking fees per remaining segment, waived only for documented medical ineligibility.
Video or chat-based intake with licensed provider; assigned care team includes board-certified obesity medicine physicians, NPs, RNs, and functional health coaches; weekly check-ins via app with dose titration; 12.7 average annual care-team touchpoints per company-published study.
Pricing and policies above were verified May 6, 2026. Always re-verify on the provider's site at the moment of purchase.
Email corrections@epioneum.com with the field, the number we have, the number you believe is correct, and a primary or secondary source. We respond within 14 days.